Selected research
Industry Research
Giant Cell Arteritis Therapeutic Industry Research Report 2026
Market perspective
The global Giant Cell Arteritis Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Giant Cell Arteritis Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Giant Cell Arteritis Therapeutic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Giant Cell Arteritis Therapeutic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Giant Cell Arteritis Therapeutic include Abbott, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline plc, AbbVie, Inc., Regeneron, Lahey Clinic Foundation and Kiniksa Pharmaceuticals, Ltd., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Giant Cell Arteritis Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Giant Cell Arteritis Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Giant Cell Arteritis Therapeutic Market by Company
Abbott
Sanofi
Johnson & Johnson Services, Inc.
Novartis AG
GlaxoSmithKline plc
AbbVie, Inc.
Regeneron
Lahey Clinic Foundation
Kiniksa Pharmaceuticals, Ltd.
Johns Hopkins Hospital
Fortis Healthcare
F. Hoffmann-La Roche Ltd.
Duke University Health System
Bristol-Myers Squibb Company
American College of Rheumatology
Giant Cell Arteritis Therapeutic Segment by Type
Tocilizumab
Prednisone
Methotrexate
Aspirin
Giant Cell Arteritis Therapeutic Segment by Application
Anticoagulants
Immunosuppressive Agents
Corticosteroids
Others
Giant Cell Arteritis Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Giant Cell Arteritis Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Giant Cell Arteritis Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Giant Cell Arteritis Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Giant Cell Arteritis Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tocilizumab
- Prednisone
- Methotrexate
- Aspirin
Applications
- Anticoagulants
- Immunosuppressive Agents
- Corticosteroids
- Others
Companies covered
- Abbott
- Sanofi
- Johnson & Johnson Services, Inc.
- Novartis AG
- GlaxoSmithKline plc
- AbbVie, Inc.
- Regeneron
- Lahey Clinic Foundation
- Kiniksa Pharmaceuticals, Ltd.
- Johns Hopkins Hospital
- Fortis Healthcare
- F. Hoffmann-La Roche Ltd.
- Duke University Health System
- Bristol-Myers Squibb Company
- American College of Rheumatology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Giant Cell Arteritis Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tocilizumab
- 2.2.3 Prednisone
- 2.2.4 Methotrexate
- 2.2.5 Aspirin
- 2.3 Giant Cell Arteritis Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Anticoagulants
- 2.3.3 Immunosuppressive Agents
- 2.3.4 Corticosteroids
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Giant Cell Arteritis Therapeutic Breakdown Data by Type
- 3.1 Global Giant Cell Arteritis Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Giant Cell Arteritis Therapeutic Forecasted Market Size by Type (2027-2032)
4 Giant Cell Arteritis Therapeutic Breakdown Data by Application
- 4.1 Global Giant Cell Arteritis Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Giant Cell Arteritis Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Giant Cell Arteritis Therapeutic Market Perspective (2021-2032)
- 5.2 Global Giant Cell Arteritis Therapeutic Growth Trends by Region
- 5.2.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Giant Cell Arteritis Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Giant Cell Arteritis Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Giant Cell Arteritis Therapeutic Market Dynamics
- 5.3.1 Giant Cell Arteritis Therapeutic Industry Trends
- 5.3.2 Giant Cell Arteritis Therapeutic Market Drivers
- 5.3.3 Giant Cell Arteritis Therapeutic Market Challenges
- 5.3.4 Giant Cell Arteritis Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Giant Cell Arteritis Therapeutic Players by Revenue
- 6.1.1 Global Top Giant Cell Arteritis Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Giant Cell Arteritis Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Giant Cell Arteritis Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Giant Cell Arteritis Therapeutic Head Office and Area Served
- 6.4 Global Giant Cell Arteritis Therapeutic Players, Product Type & Application
- 6.5 Global Giant Cell Arteritis Therapeutic Manufacturers Established Date
- 6.6 Global Giant Cell Arteritis Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Giant Cell Arteritis Therapeutic Market Size (2021-2032)
- 7.2 North America Giant Cell Arteritis Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Giant Cell Arteritis Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Giant Cell Arteritis Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Giant Cell Arteritis Therapeutic Market Size (2021-2032)
- 8.2 Europe Giant Cell Arteritis Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Giant Cell Arteritis Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Giant Cell Arteritis Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Giant Cell Arteritis Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Giant Cell Arteritis Therapeutic Market Size (2021-2032)
- 10.2 South America Giant Cell Arteritis Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Giant Cell Arteritis Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Giant Cell Arteritis Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Giant Cell Arteritis Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.1.4 Abbott Giant Cell Arteritis Therapeutic Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.2.4 Sanofi Giant Cell Arteritis Therapeutic Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Johnson & Johnson Services, Inc.
- 12.3.1 Johnson & Johnson Services, Inc. Company Information
- 12.3.2 Johnson & Johnson Services, Inc. Business Overview
- 12.3.3 Johnson & Johnson Services, Inc. Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.3.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
- 12.3.5 Johnson & Johnson Services, Inc. Recent Developments
- 12.4 Novartis AG
- 12.4.1 Novartis AG Company Information
- 12.4.2 Novartis AG Business Overview
- 12.4.3 Novartis AG Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.4.4 Novartis AG Giant Cell Arteritis Therapeutic Product Portfolio
- 12.4.5 Novartis AG Recent Developments
- 12.5 GlaxoSmithKline plc
- 12.5.1 GlaxoSmithKline plc Company Information
- 12.5.2 GlaxoSmithKline plc Business Overview
- 12.5.3 GlaxoSmithKline plc Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.5.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Portfolio
- 12.5.5 GlaxoSmithKline plc Recent Developments
- 12.6 AbbVie, Inc.
- 12.6.1 AbbVie, Inc. Company Information
- 12.6.2 AbbVie, Inc. Business Overview
- 12.6.3 AbbVie, Inc. Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.6.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
- 12.6.5 AbbVie, Inc. Recent Developments
- 12.7 Regeneron
- 12.7.1 Regeneron Company Information
- 12.7.2 Regeneron Business Overview
- 12.7.3 Regeneron Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.7.4 Regeneron Giant Cell Arteritis Therapeutic Product Portfolio
- 12.7.5 Regeneron Recent Developments
- 12.8 Lahey Clinic Foundation
- 12.8.1 Lahey Clinic Foundation Company Information
- 12.8.2 Lahey Clinic Foundation Business Overview
- 12.8.3 Lahey Clinic Foundation Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.8.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Portfolio
- 12.8.5 Lahey Clinic Foundation Recent Developments
- 12.9 Kiniksa Pharmaceuticals, Ltd.
- 12.9.1 Kiniksa Pharmaceuticals, Ltd. Company Information
- 12.9.2 Kiniksa Pharmaceuticals, Ltd. Business Overview
- 12.9.3 Kiniksa Pharmaceuticals, Ltd. Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.9.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
- 12.9.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments
- 12.10 Johns Hopkins Hospital
- 12.10.1 Johns Hopkins Hospital Company Information
- 12.10.2 Johns Hopkins Hospital Business Overview
- 12.10.3 Johns Hopkins Hospital Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.10.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Portfolio
- 12.10.5 Johns Hopkins Hospital Recent Developments
- 12.11 Fortis Healthcare
- 12.11.1 Fortis Healthcare Company Information
- 12.11.2 Fortis Healthcare Business Overview
- 12.11.3 Fortis Healthcare Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.11.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Product Portfolio
- 12.11.5 Fortis Healthcare Recent Developments
- 12.12 F. Hoffmann-La Roche Ltd.
- 12.12.1 F. Hoffmann-La Roche Ltd. Company Information
- 12.12.2 F. Hoffmann-La Roche Ltd. Business Overview
- 12.12.3 F. Hoffmann-La Roche Ltd. Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.12.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
- 12.12.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 12.13 Duke University Health System
- 12.13.1 Duke University Health System Company Information
- 12.13.2 Duke University Health System Business Overview
- 12.13.3 Duke University Health System Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.13.4 Duke University Health System Giant Cell Arteritis Therapeutic Product Portfolio
- 12.13.5 Duke University Health System Recent Developments
- 12.14 Bristol-Myers Squibb Company
- 12.14.1 Bristol-Myers Squibb Company Company Information
- 12.14.2 Bristol-Myers Squibb Company Business Overview
- 12.14.3 Bristol-Myers Squibb Company Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.14.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Portfolio
- 12.14.5 Bristol-Myers Squibb Company Recent Developments
- 12.15 American College of Rheumatology
- 12.15.1 American College of Rheumatology Company Information
- 12.15.2 American College of Rheumatology Business Overview
- 12.15.3 American College of Rheumatology Revenue in Giant Cell Arteritis Therapeutic Business (2021-2026)
- 12.15.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Product Portfolio
- 12.15.5 American College of Rheumatology Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst